Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of QR-333 for the Treatment of Symptomatic Diabetic Peripheral Neuropathy

NCT00568035 is registered in ClinicalTrials.gov with Quigley Pharma, Inc. as lead sponsor.

NCT NCT00568035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00568035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of QR-333 for the Treatment of Symptomatic Diabetic Peripheral Neuropathy
Lead sponsor
Quigley Pharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2006
Completion date
November 30, 2008
Enrollment
140 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic neuropathy